|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Timcodar
|
MedKoo Code#: 202926
|
|
Name: Timcodar
|
|
CAS#: 183313-30-6,
179033-51-3 (free base).
Synonym:
Timcodar dimesilate, VX-853.
Chemical name:
N1-Benzyl-4-chloro-N2-methyl-N2-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-N1-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]-L-phenylalaninamide
dimethanesulfonate.
IUPAC/Chemical name:
(S)-N-benzyl-3-(4-chlorophenyl)-N-(1,5-di(pyridin-4-yl)pentan-3-yl)-2-(N-methyl-2-oxo-2-(3,4,5-trimethoxyphenyl)acetamido)propanamide
dimethanesulfonate
|
|
Chemical structure
|
Theoretical analysis
|
|
|
Timcodar (free base)
Chemical Formula: C43H45ClN4O6
Exact Mass: 748.30276
Molecular Weight: 749.29
m/z: 748.30276 (100.0%), 749.30612 (46.5%),
750.29981 (32.0%), 751.30317 (14.9%), 750.30947 (10.6%),
752.30652 (3.4%), 751.31283 (1.6%), 749.29980 (1.5%), 750.30701
(1.2%)
Elemental Analysis: C, 68.93; H, 6.05; Cl,
4.73; N, 7.48; O, 12.81
Timcodar dimesylate
Chemical Formula: C45H53ClN4O12S2
Molecular Weight: 941.5
Elemental Analysis: C, 57.41; H, 5.67; Cl,
3.77; N, 5.95; O, 20.39; S, 6.81
|
|
Availability and price:
Timcodar, 98% (HPLC), is available
through custom synthesis
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
Timcodar (VX-853) is
a Novel Multidrug
Resistance Inhibitor. Timcodar was under clinical trials to treat
cancaners and other diseases. Timcodar potentiated the activity
of ethidium bromide (EtBr), a model efflux substrate, against three
clinically significant gram-positive pathogens: Staphylococcus aureus,
Enterococcus faecalis, and Streptococcus pneumoniae. Similar to
reserpine, VX-853 directly blocked EtBr efflux in S. aureus.
Furthermore, VX-853 was effective in lowering the MICs of several
clinically used antibiotics, including fluoroquinolones, suggesting that
VX-853 are representatives of a new class of bacterial efflux inhibitors
with the potential for use in combination therapy. [source: Antimicrob
Agents Chemother. 2004 Nov;48(11):4171-6.]
Current developer:
Vertex (Originator).
1: Bayés M, Rabasseda X, Prous JR. Gateways to
clinical trials. Methods Find Exp Clin Pharmacol. 2006 Oct;28(8):533-91.
PubMed PMID: 17136234.
2: Hahn K, Sirdofsky M, Brown A, Ebenezer G, Hauer P, Miller C,
Polydefkis M. Collateral sprouting of human epidermal nerve fibers
following intracutaneous axotomy. J Peripher Nerv Syst. 2006
Jun;11(2):142-7. PubMed PMID: 16787512.
3: Polydefkis M, Sirdofsky M, Hauer P, Petty BG, Murinson B, McArthur
JC. Factors influencing nerve regeneration in a trial of timcodar
dimesylate. Neurology. 2006 Jan 24;66(2):259-61. PubMed PMID: 16434669.
4: Mitchell AM, Tom M, Mortimer RH. Thyroid hormone export from cells:
contribution of P-glycoprotein. J Endocrinol. 2005 Apr;185(1):93-8.
PubMed PMID: 15817830.
5: Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in
bacteria by the novel multidrug resistance inhibitors biricodar (VX-710)
and timcodar (VX-853). Antimicrob Agents Chemother. 2004
Nov;48(11):4171-6. PubMed PMID: 15504837; PubMed Central PMCID:
PMC525397.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
